Reversal of multidrug resistance in murine lymphoma cells by amphiphilic dihydropyridine antioxidant derivative

Anticancer Research

Volumn 30, Issue 10, 2010, Pages 4063-4069

  Cindric, Marina ^a   Cipak, Ana ^b   Serly, Julianna ^c   Plotniece, Aiva ^d   Jaganjac, Morana ^b   Mrakovcic, Lidija ^b   Lovakovic, Tomislava ^e   Dedic, Azra ^f   Soldo, Ivo ^g   Duburs, Gunars ^d   Zarkovic, Neven ^b   Molnár, József ^c  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b RUDER BO KOVI INSTITUTE   (Croatia)

^c UNIVERSITY OF SZEGED   (Hungary)

^d LATVIAN INSTITUTE OF ORGANIC SYNTHESIS   (Latvia)

^e JOSIP JURAJ STROSSMAYER UNIVERSITY OF OSIJEK   (Croatia)

^f Biomedica Medizinprodukte GmbH and Co KG   (Austria)

^g Sveti Duh General Hospital   (Croatia)

Author keywords

Antioxidant; Cancer; Dihydropyridine derivative; Doxorubicin; MDR reversal; Oxidative stress

Indexed keywords

AMPHOPHILE; DIHYDROPYRIDINE; DOXORUBICIN; K 2 11; MULTIDRUG RESISTANCE PROTEIN 1; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; LYMPHOMA CELL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIOXIDANTS; DIHYDROPYRIDINES; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; LEUKEMIA L5178; LYMPHOMA, T-CELL; MICE; P-GLYCOPROTEIN; REACTIVE OXYGEN SPECIES; TRANSFECTION;

EID: 78650232339     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Szabó D and Molnár J: The role of stereoselectivity of chemosensitizers in the reversal of multidrug resistance of mouse lymphoma cells. Anticancer Res 18: 3039-3044, 1998.
2. Penzotti JE, Lamb ML, Evensen E and Grootenhuis PD: A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein. J Med Chem 45: 1737-1740, 2002.
3. Vaughan M: Oxidative modification of macromolecules. Minireview Series. J Biol Chem 272: 18513, 1997.
4. Khaitan D and Dwarakanath BS: Endogenous and induced oxidative stress in multi-cellular tumor spheroids: implications for improving tumor therapy. Indian J Biochem Biophys 46: 16-24, 2009.
5. Molnár J, Szabó D, Mándi Y, Mucsi I, Fischer J, Varga A, König S and Motohashi N: Multidrug resistance reversal in mouse lymphoma cells by heterocyclic compounds. Anticancer Res 18: 3033-3038, 1998.
6. Molnár J, Gyémánt N, Tanaka M, Hohmann J, Bergman-Leitner E, Molnár P, Deli J, Didiziapetris R and Umbelino Ferreira MJ: Inhibition of multidrug resistance of cancer cells by natural diterpenes, triterpenes and carotenoids. Curr Pharm Des 11: 1-25, 2005.
7. Triggle DJ: 1,4-Dihydropyridines as calcium channel ligands and privileged structures. Cell Mol Neurobiol 23: 293-303, 2003.
8. Pastan I, Gottesman MM, Ueda K, Lovelace E, Rutherford AV and Willingham MC: A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci USA 85: 4486-4490, 1988.
9. Choi K, Frommel TO, Stern RK, Perez CF, Kriegler M, Tsuruo T and Roninson IB: Multidrug resistance after retroviral transfer of the human MDR1 gene correlates with P-glycoprotein density in the plasma membrane and is not affected by cytotoxic selection. Proc Natl Acad Sci USA 88: 7386-7390, 1991.
10. Plotniece A, Pajuste K, Kaldre D, Cekavicus B, Vigante B, Turovska B, Belyakov S, Sobolev A and Duburs G: Oxidation of cationic 1,4-dihydropyridine derivatives as model compounds for putative gene delivery agents. Tetrahedron 65: 8344-8349, 2009.
11. Cazacu M, Oniu T, Lungoci C, Mihailov A, Cipak A, Klinger R, Weiss T and Zarkovic N: The influence of Isorel on the advanced colorectal cancer. Cancer Biother Radiopharm 18: 27-34, 2003.
12. Cipak A, Borovic S, Scukanec-Spoljar M, Kirac I and Zarkovic N: Possible involvment of 4-hydroxynonenal in splenocyte regulated liver regeneration. BioFactors 24: 217-226, 2005.
13. Kalinic JF, Ramakrishnan N and McClain DE: The antioxidant Trolox enhances the oxidation of 2′7′-dichlorofluorescin to 2′7′-dichlorofluorescein. Free Radie Res 26: 37-47, 1997.
14. Krishna R and Mayer LD: Multidrug resistance (MDR) in cancer mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 11: 265-283, 2000.
15. Tsuruo T, Iida H, Tsukagoshi S and Sakurai Y: Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967-1972, 1981.
16. Voigt B, Coburger C, Molnar J and Hilgeroth A: Structure-activity relationships of novel N-acyloxy-1,4-dihydropyridines as P-glycoprotein inhibitors. Bioorg Med Chem 15: 5110-5113, 2007.
17. Miri R and Mehdipour A: Dihydropyridines and atypical MDR: A novel perspective of designing general reversal agents for both typical and atypical MDR. Bioorg Medic Chem 16: 8329-8334, 2008.
18. Toyokuni S, Okamoto K, Yodoi J and Hiai H: Persistent oxidative stress in cancer. FEBS Lett 358: 1-3, 1995.
19. Hileman EO, Liu J, Albitar M, Keating MJ and Huang P: Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol 53: 209-219, 2004.
20. Lee YJ, Galoforo SS, Berns CM, Chen JC, Davis BH, Sim JE, Corry PM and Spitz DR: Glucose deprivation-induced cytotoxicity and alterations in mitogen-activated protein kinase activation are mediated by oxidative stress in multidrug-resistant human breast carcinoma cells. J Biol Chem 273: 5294-5299, 1998.
21. Spitz DR, Sim JE, Ridnour LA, Galoforo SS and Lee YJ: Glucose deprivation-induced oxidative stress in human tumor cells. Ann NY Acad Sci 899: 349-362, 2000.
22. Pelicano H, Carney D and Huang P: ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 7: 97-110, 2004.
23. Zhou S, Palmeira CM and Wallace KB: Doxorubicin-induced persistent oxidative stress to cardiac myocytes. Tox Lett 121: 151-157, 2001.
24. Berthiaume JM, Oliveira PJ, Fariss MW and Wallace KB: Dietary vitamin E decreases doxorubicin-induced oxidative stress without preventing mitochondrial dysfunction. Cardiovasc Toxicol 15: 257-267, 2005.
25. Ciaccio M, Valenza M, Tesoriere L, Bongiorno A, Albiero R and Livrea MA: Vitamin A inhibits doxorubicin-induced membrane lipid peroxidation in rat tissues in vivo. Arch Biochem Biophys 302: 103-108, 1993.
26. Gutteridge JM: Lipid peroxidation and possible hydroxyl radical formation stimulated by the self-reduction of a doxorubicin-iron (III) complex. Biochem Pharmacol 33: 1725-1728, 1984.
27. Praet M and Ruysschaert JM: In vivo and in vitro mitochondrial membrane damages induced in mice by adriamycin and derivatives. Biochim Biophys Acta 1149: 79-85, 1993.
28. Bachur NR, Gordon SL and Gee MW: A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer Res 38: 1745-1750, 1978.
29. Kimura T, Fujita I, Itoh N, Muto N, Nakanishi T, Takahashi K, Azuma J and Tanaka K: Metallothionein acts as a cytoprotectant against doxorubicin toxicity. J Pharmacol Exp Ther 292: 299-302, 2000.
30. Kang YJ, Chen Y and Epstein PN: Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice. J Biol Chem 271: 12610-12616, 1996. (Pubitemid 26160936)
31. Kang YJ, Chen Y, Yu A, Voss-McCowan M and Epstein PN: Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity. J Clin Invest 100: 1501-1506, 1997.
32. Cooke L, Grill M, Shirahatti N and Mahadevan D: MDR transporters as therapeutic targets in cancer. Sci Med 10: 30-41, 2005.
33. Wartenberg M, Ling FC, Cchallenberg M, Baumer AT, Petrat K, Hescheler J and Sauer H: Down-regulation of intrinsic P-glycoprotein expression in multicellular prostate tumor spheroids by reactive oxygen species. J Biol Chem 276: 17420-17428, 2001.
34. Schieven GL, Kirihara JM, Myers DE, Ledbetter JA and Uckun FM: Reactive oxygen intermediates activate NF-κB in a tyrosine kinase-dependent mechanism and in combination with vanadate activate the p561ck and p59fyn tyrosine kinases in human lymphocytes. Blood 82: 1212-1220, 1993.
35. Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N, Gielen J, Merville MP and Boursn V: NF-κB transcription factor induces drug resistance through MDRI expression in cancer cells. Oncogene 22: 90-97, 2003.
36. Kalyanaraman B, Sealy RC and Sinha BK: An electron spin resonance study of the reduction of peroxides by anthracycline semiquinones. Biochem Biophys Acta 779: 270-275, 1984. (Pubitemid 14077938)